ESR1 and breast carcinoma: In all, we demonstrate that AR promotes ER-mutant BC growth, OXPHOS, and resistance to palmitate lipotoxicity under conditions mimicking standard-of-care AI therapy under which ER-mutant metastatic breast cancer develops (Fig. 7).